Pages that link to "Q81683829"

The following pages link to Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives (Q81683829):

Displaying 39 items.

• Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples (Q24289511) (← links)
• The role of oxidative stress in Parkinson's disease (Q24307946) (← links)
• Neuroprotection by pharmacologic blockade of the GAPDH death cascade (Q24545207) (← links)
• Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis (Q24658203) (← links)
• The diverse functions of GAPDH: views from different subcellular compartments (Q28291106) (← links)
• I1 imidazoline receptor: novel potential cytoprotective target of TVP1022, the S-enantiomer of rasagiline (Q28485219) (← links)
• Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro (Q33825775) (← links)
• The cardioprotective efficacy of TVP1022 in a rat model of ischaemia/reperfusion. (Q35036171) (← links)
• The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys (Q35196195) (← links)
• Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness (Q35566604) (← links)
• Targeting Dopamine in Acute Traumatic Brain Injury (Q35720254) (← links)
• A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement (Q36177001) (← links)
• Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease. (Q36364388) (← links)
• Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease (Q36468704) (← links)
• ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy. (Q37043396) (← links)
• Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease? (Q37082042) (← links)
• Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease (Q37358676) (← links)
• Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival (Q37599639) (← links)
• Nitric Oxide Signaling and Nitrosative Stress in Neurons: Role forS-Nitrosylation (Q37784821) (← links)
• Safety of rasagiline for the treatment of Parkinson's disease (Q37859776) (← links)
• Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline (Q37939755) (← links)
• Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects (Q37963572) (← links)
• Targeting Mitochondria for Neuroprotection in Parkinson's Disease (Q37974311) (← links)
• Progression of motor symptoms in Parkinson’s disease (Q37974751) (← links)
• Adjunctive therapy in Parkinson's disease: the role of rasagiline (Q38026830) (← links)
• Metal dyshomeostasis and inflammation in Alzheimer's and Parkinson's diseases: possible impact of environmental exposures (Q38109630) (← links)
• Rasagiline and rapid symptomatic motor effect in Parkinson's disease: review of literature. (Q38497529) (← links)
• Rasagiline in treatment of Parkinson's disease. (Q39315311) (← links)
• Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells (Q39681299) (← links)
• The neuroprotective agent Rasagiline mesylate attenuates cardiac remodeling after experimental myocardial infarction (Q41239263) (← links)
• Prediction of multi-target networks of neuroprotective compounds with entropy indices and synthesis, assay, and theoretical study of new asymmetric 1,2-rasagiline carbamates (Q42920103) (← links)
• Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression (Q43138022) (← links)
• Rasagiline delays retinal degeneration in a mouse model of retinitis pigmentosa via modulation of Bax/Bcl-2 expression. (Q47710236) (← links)
• Apoptosis inhibition in T cells triggers the expression of proinflammatory cytokines--implications for the CNS. (Q48194760) (← links)
• Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat. (Q48334325) (← links)
• N-Methyl, N-propynyl-2-phenylethylamine (MPPE), a Selegiline Analog, Attenuates MPTP-induced Dopaminergic Toxicity with Guaranteed Behavioral Safety: Involvement of Inhibitions of Mitochondrial Oxidative Burdens and p53 Gene-elicited Pro-apoptotic C (Q48451343) (← links)
• Rasagiline interferes with neurodegeneration in the Prph2/rds mouse (Q54351583) (← links)
• α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease (Q64870070) (← links)
• Targeting immunometabolism as an anti-inflammatory strategy (Q90053663) (← links)